Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.46 |
| ▸ | EPAS1 | Q99814 | 8/20 | 0.46 |
| ▸ | COXFA4 | O00483 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4484899 | 0.81 | HIF1A (0.52) | HPGDCA1CA2HIF1AEPAS1 | |
| SCHEMBL5868243 | 0.74 | HIF1A (0.54) | HPGDCA1HIF1AEPAS1COXFA4 | |
| SCHEMBL2832072 | 0.72 | HIF1A (0.49) | HPGDHIF1AEPAS1COXFA4ALDH1A1 | |
| SCHEMBL4484870 | 0.72 | CA1 (0.50) | HPGDCA1CA2TRPV1ALDH1A1 | |
| SCHEMBL4470956 | 0.72 | CA1 (0.47) | HPGDCA1CA2TRPV1 | |
| SCHEMBL4492535 | 0.72 | CA1 (0.47) | HPGDCA1CA2TRPV1ALDH1A1 | |
| SCHEMBL17781624 | 0.71 | ALDH1A1 (0.47) | HPGDHIF1AEPAS1COXFA4ALDH1A1 | |
| SCHEMBL9032911 | 0.71 | HIF1A (0.54) | HIF1AEPAS1 | |
| SCHEMBL5088894 | 0.70 | TRPV1 (0.68) | HPGDCA1CA2TRPV1 | |
| SCHEMBL6935054 | 0.68 | HIF1A (0.43) | HPGDCA1HIF1AEPAS1COXFA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534903-B2 | Use of amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl-compounds in the treatment of cardiac arrhythmia and other disease states | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-05-19 | — | — | US | disclosed |
| EP-1678130-B1 | AMIDOMETHYL-SUBSTITUTED 2-(4-SULFONILAMINO)-3-HIDROXY-3,4-DIHYDRO-2H-CHROMIUM-6-YL-DERIVATIVES AND DRUGS CONTAINING SAID COMPOUNDS | SOLVAY PHARM GMBH (DE) | 2008-08-20 | — | — | EP | disclosed |
| US-20080113999-A1 | Use of Amidomethyl-Substituted 2-(4-Sulfonylamino)-3-Hydroxy-3,4-Dihydro-2H-Chromen-6-yl-Compounds in the Treatment of Cardiac Arrhythmia and Other Disease States | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-05-15 | — | — | US | disclosed |
| US-7368582-B2 | Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-05-06 | — | — | US | disclosed |
| US-20050148659-A1 | Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148659-A1 | Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP4B1, CYP3A4 | HPGD 771/4885CA1 4689/4885CA2 3695/4885 |
| US-20080113999-A1 | Use of Amidomethyl-Substituted 2-(4-Sulfonylamino)-3-Hydroxy-3,4-Dihydro-2H-Chromen-6-yl-Compounds in the Treatment of Cardiac Arrhythmia and Other Disease States | KCNH1, RYR2, KCNJ2 | HPGD 1732/4885CA1 3342/4885CA2 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.